FDA “Breakthrough Therapy” Designations
This article was originally published in Pharmaceutical Approvals Monthly
Breakthrough status was introduced in FDASIA to facilitate development and review of drugs to treat serious/life-threatening diseases where there is early evidence of a substantial improvement over existing therapies.
You may also be interested in...
STADA Strengthens Specialty Partnership Role Via US Filing
Antoine Marchal, Franchise Head PCR Core Labs - BA Molecular Diagnostics at Qiagen outlines how NeuModx will strengthen its position in the infectious disease space.
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.